Endari Will Soon Be Available to Sickle Cell Patients in the US Military
The oral therapy Endari (L-glutamine), developed by Emmaus Life Sciences, will soon be made available to patients with sickle cell disease in the United States military, along with 9.4 million of their beneficiaries, thanks to a new distribution agreement, the company announced. The agreement is between Emmaus and…